Dec 23 The U.S. Food and Drug Administration on
Friday said it has approved Biogen Inc's drug to treat
spinal muscular atrophy, the leading genetic cause of death in
The drug, nusinersen, which was discovered by Ionis
Pharmaceuticals and licensed to Biogen, will be sold
under the brand name Spinraza.
It is the first FDA-approved medicine for spinal muscular
atrophy, a devastating disease that affects about one in 10,000
live births. The agency approved it for use across the full
range of patients with the disease.
(Reporting by Bill Berkrot in New York)